Pfizer’s COVID vaccines and Paxlovid doses returned, causing huge quarterly loss.
Pfizer Reports Significant Losses as Demand for COVID Vaccines and Paxlovid Decreases
Pfizer, the pharmaceutical giant, experienced a substantial loss in the third quarter, according to CNBC. The company’s earnings call revealed a decrease in demand for its COVID-19 vaccines and the antiviral medication Paxlovid.
The losses were attributed to a write-off of $5.6 billion, primarily due to Paxlovid and its vaccine, Comirnaty, as announced by Pfizer. Paxlovid accounted for $4.7 billion in losses, while the mRNA vaccine contributed $900 million.
Despite these losses, Pfizer reported a quarterly revenue of $13.2 billion, which was a 42 percent decrease compared to the second quarter of 2022. The revenue generated from Pfizer’s COVID shots during July to September was $1.31 billion, a 70 percent decrease from the previous year.
Furthermore, sales of Paxlovid plummeted by 97 percent year-over-year. The company agreed to take back nearly 8 million unused courses of Paxlovid from the U.S. government, along with its vaccine inventory, as reported by Reuters.
“One-time items include a non-cash revenue reversal of approximately $4.2 billion related to the return of an estimated 7.9 million treatment courses of U.S. government [emergency use authorization]-labeled Paxlovid expected in the fourth quarter of 2023 and a non-cash charge of $5.6 billion recorded to Cost of Sales in the third quarter of 2023 for COVID products inventory write-offs and other charges,” it said.
Shares of Pfizer opened at $30.32 on Tuesday morning, a significant decrease from its record high of over $57 per share in December 2021. This marked the first time the company reported losses since 2019.
The declining demand for vaccines and COVID treatments was attributed to “population-wide immunity,” according to Reuters. The annual vaccination rates have dropped sharply as population-wide immunity has increased.
Pfizer plans to reduce its operating costs through a $3.5 billion program announced prior to the reported losses. Despite the setbacks, the company expressed optimism about its non-COVID drugs, highlighting their strong performance in the third quarter of 2023.
“We are encouraged by the strong performance of Pfizer’s non-COVID products in the third quarter of 2023, including significant contributions from new launches and robust year-over-year growth for several key in-line brands,” Pfizer Chairman and CEO Albert Bourla said in a statement.
Chief Financial Officer David Denton added, “We are extremely pleased by the strong 10% operational revenue growth of Pfizer’s non-COVID products in the third quarter of 2023.”
A Note from Our Founder:
Every morning, we at The Western Journal wake up and pursue our mission of giving you the important information you need about what’s happening in America.
We can’t do that without your help.
America has been on the receiving end of false narratives. The purpose of these false narratives is to make you feel powerless. The Western Journal empowers you by breaking these false narratives.
But I wouldn’t be honest with you today if I didn’t let you know that the future of The Western Journal is in jeopardy without your help.
Silicon Valley and the Big Tech tyrants have done everything they can to put The Western Journal out of business. Our faithful donors and subscribers have kept us going.
If you’ve never chosen to donate, let me be honest: We need your help today.
Please don’t wait one minute. Donate right now – our situation in America is dire. Our country hangs by a thread, and The Western Journal stands for truth in this difficult time.
Please stand with us by donating today.
Floyd G. Brown
Founder of The Western Journal
The post Pfizer Suffers Massive Quarterly Loss as COVID Vaccines and Paxlovid Doses Are Returned appeared first on The Western Journal.
How did the decline in demand for COVID-19 vaccines and Paxlovid impact Pfizer’s overall revenue?
S://www.westernjournal.com/category/us-news/”>US News, World News, Politics, Opinion and more. Join us in our mission and let’s rebuild a bright and prosperous future for America together.
The pharmaceutical giant Pfizer has reported significant losses in the third quarter of 2023 due to a decrease in demand for its COVID-19 vaccines and the antiviral medication Paxlovid. The company’s earnings call revealed a write-off of $5.6 billion, primarily attributed to Paxlovid and its vaccine Comirnaty. The losses highlight the impact of declining demand for COVID-related products and the challenges faced by pharmaceutical companies in adapting to changing market conditions.
Pfizer recorded a quarterly revenue of $13.2 billion, a 42 percent decrease compared to the previous quarter. This decline is largely driven by a 70 percent decrease in revenue generated from Pfizer’s COVID shots during the third quarter of 2023, compared to the same period the previous year. Additionally, sales of Paxlovid plummeted by 97 percent year-over-year, prompting Pfizer to agree to take back nearly 8 million unused courses of the medication from the U.S. government.
The declining demand for COVID-19 vaccines and treatments can be attributed to increasing population-wide immunity. As vaccination rates have dropped sharply, the need for COVID-related products has decreased. This trend reflects a positive development in the battle against the pandemic, but it poses challenges for pharmaceutical companies that heavily rely on COVID-related sales.
Despite these setbacks, Pfizer remains optimistic about its non-COVID drugs. The company highlighted the strong performance of its non-COVID products in the third quarter, with significant contributions from new launches and robust year-over-year growth for key in-line brands. Pfizer’s Chairman and CEO, Albert Bourla, expressed encouragement regarding the performance of their non-COVID products, signaling potential growth areas for the company.
In response to the reported losses, Pfizer plans to reduce its operating costs through a $3.5 billion program announced prior to the earnings call. This cost reduction strategy aims to optimize the company’s financial performance and mitigate the impact of declining COVID-related sales.
The financial downturn experienced by Pfizer is notable as it marks the first reported losses for the company since 2019. The decrease in demand for COVID-19 vaccines and Paxlovid underscores the ongoing challenges faced by pharmaceutical companies in navigating the ever-changing landscape of the global health crisis.
As Pfizer and other pharmaceutical companies adapt to shifting market dynamics, it remains crucial to focus on the development of innovative non-COVID products that can sustain their revenue stream. The lessons learned from managing the COVID-19 pandemic can inform future strategies and help companies like Pfizer navigate future challenges in the healthcare industry.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
Now loading...